Peculiarities of pharmacological prevention strategy of pancreatic complications after endoscopic papillosphincterotomy for choledocholithiasis

The most frequent complication of endoscopic papillosphincterotomy (EPST) is acute pancreatitis. This complication is supposed to be based on mechanical, chemical, hydrostatic, enzymatic and thermal impact on pancreatic ducts and parenchyma. According to different literature data, the incidence of post-EPST pancreatitis (PEP) varies from 30 to 40%, and the mortality rate is 2-10%. The aim of the investigation was to expand information about peculiarities of early diagnostics and prevention of post-EST pancreatitis at the present stage. To reach the set goal we analyzed 559 case histories of patients with diagnosed cholelithiasis, 319 of them underwent EPST. During the study it was found out, that elevated neutrophils/lymphocytes ratio over 4,96 (p=0,001), high LDH level over 250 IU/ml (p=0,01), as well as C-reactive to albumin index over 0,180 (p=0,001) are reliable markers of early diagnosis. Also, indirect diagnostic markers of PEEP are biochemical signs of cholestasis and cytolysis of hepatocytes, as well as hyperglycemia combined with glucosuria. We consider the inclusion of intraoperative injections of papillotomy wound margins with Epinephrine in combination with subsequent Somatostatin administration in combination with rectal Diclofenac and intravenous hydration with Reamberin to be the most effective strategy for PEP prevention. Thus, we can conclude that despite the ongoing research and the search for effective algorithms for the prevention and early diagnosis of PEP, their data often contradict each other or simply do not confirm their effectiveness. The problem of prevention and diagnosis of PEP remains complex and requires further study. There are discrepancies, sometimes significant ones, in the current literature, which provides grounds for the development and research of new methods of early diagnosis and prevention.

pancreatitis, papillosphincterotomy, prevention, diagnosis

1. Ogura T., Imoto A., Okuda A., Fukunishi S., Higuchi K. Can Iodixanol Prevent Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis? A Prospective, Randomized, Controlled Trial. Dig Dis. 2019;37(3):255-261. doi: 10.1159/000496349.

2. Dumonceau J. M., Kapral C., Aabakken L. et al. ERCP-related adverse events: European Society of Gastro-intestinal Endoscopy (ESGE) Guideline. Endoscopy. 2020 Feb;52(2):127-149. doi: 10.1055/a-1075-4080.

3. Morales S. J., Sampath K., Gardner T. B. A Review of Prevention of Post-ERCP Pancreatitis. Gastroenterol Hepatol (N Y). 2018 May;14(5):286-292. PMID: 29991936.

4. Chen J., Wan J. H., Wu D. Y., Shu W. Q., Xia L., Lu N. H. Assessing Quality of Precut Sphincterotomy in Patients With Difficult Biliary Access: An Updated Meta-analysis of Randomized Controlled Trials. J Clin Gastroenterol. 2018 Aug;52(7):573-578. doi: 10.1097/MCG.0000000000001077.

5. Park C. H., Park S. W., Yang M. J., Moon S. H., Park D. H. Pre- and post-procedure risk prediction models for post-endoscopic retrograde cholangiopancreatography pancreatitis. Surg Endosc. 2022 Mar;36(3):2052-2061. doi: 10.1007/s00464-021-08491-1.

6. Devière J. Post-ERCP pancreatitis: still a major issue despite all efforts. Endoscopy. 2021 Apr;53(4):367-368. doi: 10.1055/a-1369-9031.

7. Buxbaum J. L., Freeman M., Amateau S. K. et al; (ASGE Standards of Practice Committee Chair). American Society for Gastrointestinal Endoscopy guideline on post-ERCP pancreatitis prevention strategies: summary and recommendations. Gastrointest Endosc. 2023 Feb;97(2):153-162. doi: 10.1016/j.gie.2022.10.005.

8. Padberg S., Tissen-Diabaté T., Dathe K. et al. Safety of diclofenac use during early pregnancy: A prospective observational cohort study. Reprod Toxicol. 2018 Apr;77:122-129. doi: 10.1016/j.reprotox.2018.02.007.

9. Liu L., Li C., Huang Y., Jin H. Nonsteroidal Anti-inflam-matory Drugs for Endoscopic Retrograde Cholan-giopan-creatography Postoperative Pancreatitis Prevention: a Systematic Review and Meta-analysis. J Gastrointest Surg. 2019 Oct;23(10):1991-2001. doi: 10.1007/s11605-018-3967-7.

10. Serrano J. P.R., de Moura D. T.H., Bernardo W. M. et al. Nonsteroidal anti-inflammatory drugs versus placebo for post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and meta-analysis. Endosc Int Open. 2019 Apr;7(4): E477-E486. doi: 10.1055/a-0862-0215.

11. Tomoda T., Kato H., Ueki T. et al.Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography. Gastroenterology. 2019 May;156(6):1753-1760.e1. doi: 10.1053/j.gastro.2019.01.267.

12. Boškoski I., Costamagna G. How to Prevent Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Gastroenterology. 2020 Jun;158(8):2037-2040. doi: 10.1053/j.gastro.2020.03.019.

13. Tse F., Liu J., Yuan Y., Moayyedi P., Leontiadis G. I. Guidewire-assisted cannulation of the common bile duct for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Cochrane Database Syst Rev. 2022 Mar 29;3(3): CD009662. doi: 10.1002/14651858.CD009662.pub3.

14. Li D. F., Yang M. F., Chang X., Wang N. N. et al. Endocut Versus Conventional Blended Electrosurgical Current for Endoscopic Biliary Sphincterotomy: A Meta-Analysis of Complications. Dig Dis Sci. 2019 Aug;64(8):2088-2094. doi: 10.1007/s10620-019-05513-w.